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Introduction
Thrombosis is one of the common 
causes for hospital admission and 
emergency room visits.1 Thrombosis is 
associated with significant morbidity and 
mortality. Hypercoagulability is a condition 
characterized by tendency to have 
thrombosis as a result of inherited and/or 
acquired defects.  
The prevalence of hypercoagulable state 
is low in the general population but is 
greater in people with genetic 
predisposition.2 Antiphospholipid antibody 
syndrome (APS) accounts for approximately 
28% of cases with hypercoagulability 
conditions, followed by activated protein C 
resistance (25%) and malignancy (15%).1 
Other conditions associated with hypercoag-
ulability states include pregnancy and 
medications. Geographic variations have 
been reported in APS as follows: Sweden 
15%, Cyprus 13% and the Middle East 
5%.3,4  
Clinicians must have a high index of 
suspicion for APS in patients with multiple 
thrombotic episodes, idiopathic DVT, or 
spontaneous abortions. An investigation for 
antiphospholipid antibodies early at 
presentation is important as it may influence 
the course of the disease. 
We present a discussion of a case, where 
a patient initially had negative lab work-up 
for APS but had positive clinical features. 
He developed positive lab work-up for APS 
during later years and was managed with 
optimum anticoagulation therapy and 
education of the patient.  
 
Case Report 
A 57-year-old Caucasian male presented 
to the emergency department with 
complaints of right upper arm pain and 
erythema. The pain was acute in onset, 
radiating towards his palm, and rated as 5/10 
(10 being the most severe pain) with no 
aggravating or relieving factors. For the 
prior month, the patient had intermittent 
pain in his right upper arm, but he did not 
seek medical treatment as the symptoms 
resolved spontaneously.  
The patient had a history of multiple 
hospitalizations. The first one was in 1970 
when he was admitted for deep vein 
thrombosis (DVT) and placed on warfarin 
for three months. After a hospitalization in 
2003 for pulmonary embolism, he was 
placed on lifelong warfarin therapy. He was 
re-admitted to the hospital in 2003 for DVT. 
He had a negative work-up for APS in terms 
of following lab parameters: APTT, lupus 
anti-coagulant, cardiolipin screen, and 
hexagonal phospholipid test. In 2010, he 
was diagnosed with APS with the following 
lab parameters: APTT of 48 seconds, lupus 
anti-coagulant was positive, cardiolipin 
screen was negative, and hexagonal 
phospholipid test was positive. He 
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underwent a right above knee amputation in 
2012 secondary to ischemia. He was non-
compliant with his medications from 2010 to 
2013. Also suspecting warfarin resistance 
due to non-compliance or due to decrease 
sensitivity of vitamin K 2,3-epoxide 
reductase to warfarin, he was switched from 
warfarin to enoxaparin. The patient’s father 
also had a history of recurrent clots.  
On physical exam, the patient’s right 
upper extremity was cool to touch, capillary 
refill was greater than ten seconds, and a 
purple discoloration of the skin extended 
from his fingertips to mid forearm. There 
was an inability to palpate a radial, ulnar, or 
brachial pulse of the right upper extremity. 
The left upper extremity had diminished, but 
had palpable pulses. There was no pain to 
palpation of either extremity. No clubbing or 
edema of either upper extremity was noted. 
A peripheral angiogram showed thrombi in 
the right brachial artery extending into right 
radial artery. He subsequently underwent 
suction thrombectomy along with tissue 
plasminogen activator infusion to the clot. A 
follow-up angiogram showed a patent right 
brachial artery. He was placed on heparin 
for twenty-four hours, then switched to 
enoxaparin sodium, and finally bridged to 
warfarin successfully. 
At the time of his recent admission, lab 
values included hemoglobin of 12.9 g/L, 
white blood count of 11,100 cells/mcL, 
mean corpuscular volume of 93.8 fL, 
glucose of 90 mg/dL, creatinine of 0.96 
mg/dL, fibrinogen of 390, INR of 1.1, and 
activated partial thromboplastin time of 61 
seconds. Labs on discharge included 
hemoglobin of 12.3 g/L, creatinine of 0.87 
mg/dL, blood urea nitrogen of 9 mg/dL, 
activated partial thromboplastin time of 25.5 
seconds, prothrombin time of 10, and INR 
of 2.5. He was advised on discharged to 
continue warfarin of 5 mg per day, 
enoxaparin 120 mg per day, and atenolol of 
50 mg per day, and follow-up with the 
surgical vascular clinic. His INR goal was 
set at 2.5-3.0. He was educated about the 
importance of being compliant with his 
management and follow up visits at time of 
discharge.  
 
Discussion 
APS is an autoimmune disease 
characterized clinically by hypercoagulable 
state.4 Its diagnosis is confirmed by the 
presence of at least one type of antibody 
(lupus anticoagulant, anti-cardiolipin 
antibody, or anti-β2-glycoprotein-I anti-
bodies) in the plasma, and the occurrence of 
at least one of the following clinical 
manifestations: venous or arterial 
thrombosis, or pregnancy morbidity5 (see 
classification criteria in appendix). The 
antibodies are directed not only against the 
epitopes on plasma proteins that are 
uncovered or generated by the binding of 
these proteins to phospholipids, but also to 
phospholipid binding proteins.6 Anti-
phospholipid antibodies (aPL) can disturb 
both pro- and anticoagulant pathways. 
Screening for these antibodies should 
include at least two phospholipid dependent 
coagulation tests: activated partial 
thromboplastin time, diluted prothrombin 
time, and diluted Russell viper venom time 
to increase specificity (identify true 
negatives).7 A mixing test should be done 
following abnormal screening and failure of 
correction of clotting time should be 
confirmed by demonstration of phospholipid 
dependence of the inhibitor (hexagonal 
phospholipid ethanolamine time).8   
The exact pathogenesis of APS is 
unknown. However, proposed hypotheses 
include activation of endothelial cells by 
antiphospholipid antibodies, interference 
with functioning of phospholipid binding 
proteins involved in coagulation, or oxidant-
mediated injury of vascular endothelium.9 
These antiphospholipid antibodies can be 
formed in the susceptible individual 
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secondary to infections, autoimmune 
disorders such as systemic lupus erythema-
tosus or rheumatic disorder, or malignancy, 
such as colon cancer, prostate cancer, or 
leukemia leading to APS.10,11 These 
antibodies bind to endothelial cells causing 
stimulation of adhesion molecule and 
creating a pro-thrombotic state.9 Close 
association exists between systemic lupus 
erythematous and APS.12,13 Keeling et al.7 
reported that patients with systemic lupus 
erythematosus who were lupus anticoagulant 
positive had a six times greater risk of 
having a thromboembolic event as compared 
to patients who were negative. Similarly, 
those with a positive cardiolipin antibody 
had twice the risk.  
Given the broad clinical presentation of 
APS, primary and secondary prevention for 
thrombosis is crucial. However, two 
prospective randomized trials reported that 
recurrences of vascular event in a low 
intensity treatment group (INR of 2-3) was 
less as compared to those in the high 
intensity group (INR of 3.1-4).14 Schluman 
et al.15 and Kearon et al.16 reported that the 
rate of recurrence of a thrombotic event is 
less if therapy is given for a longer duration 
of time. In both studies, bleeding was more 
in the high intensity group (INR 3.5-4). The 
Antiphospholipid Antibody and Stroke 
Study (APASS) showed aspirin (325 
mg/day) and low-to-moderate anticoagu-
lation were equally effective in patients with 
initial stroke irrespective of their anti-
phospholipid antibody status.17 The current 
recommendation for the management for 
APS or DVT is to have a therapeutic INR of 
2.5-3. The duration of therapy depends per 
individual case and the risk/benefit ratio.14 
Annual risk of bleeding within a therapeutic 
INR of 2-3 is 2%.9 
The American College of Chest 
Physicians Guidelines18 for arterial 
thrombosis is to treat with aspirin or low-to-
moderate intensity anticoagulation (INR of 
1.5-2.5). For cancer associated with DVT or 
pulmonary embolism, clinicians should treat 
for at least 3-6 months and preferably with 
long-term anticoagulation therapy, unless 
bleeding risk is very high. A pregnant 
patient with a history of recurrent pregnancy 
loss (< 10 weeks) should be screened for 
antiphospholipid antibodies. If positive, low 
molecular weight heparin and aspirin should 
be given throughout pregnancy.  If there is a 
history of pre-eclampsia, low dose aspirin is 
recommended. If the thrombotic event 
recurs during warfarin therapy, despite INR 
levels that are within the target range of 2.0 
to 3.0, then an alternate treatment could be 
low molecular weight heparin or anti-Xa 
therapy. 
APS is present if at least one of the 
following clinical criteria and one of the 
laboratory criteria are met.4 For vascular 
thrombosis, episodes of arterial, venous, or 
small vessel thrombosis must be present in 
any tissue or organ or plasma on two or 
more occasions at least 12 weeks apart. 
Thrombosis must be confirmed by objective 
and validated criteria (i.e., unequivocal 
findings of appropriate imaging studies or 
histopathology). For histopathologic con-
firmation, thrombosis should be present 
without significant evidence of inflam-
mation in the vessel wall.  
For pregnancy morbidity, either one of 
three conditions must be present.5 They 
include: (1) one or more unexplained deaths 
of a morphologically normal fetus at or 
beyond the 10th week of gestation, with 
normal fetal morphology documented by 
ultrasound or by direct examination of the 
fetus, (2) one or more premature births of a 
morphologically normal neonate before the 
34th week of gestation because of eclampsia 
or severe pre-eclampsia defined according to 
standard definitions, or  recognized features 
of placental insufficiency, or  (3) three or 
more unexplained consecutive spontaneous 
abortions before the 10th week of gestation, 
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with maternal anatomic or hormonal 
abnormalities and paternal and maternal 
chromosomal causes have been excluded. 
Laboratory criteria for APS includes: (1) 
lupus anticoagulant (LA) present in plasma, 
on two or more occasions at least 12 weeks 
apart, detected according to the guidelines of 
the International Society on Thrombosis and 
Haemostasis (Scientific Subcommittee on 
LAs/phospholipid-dependent antibodies)17, 
(2) anticardiolipin (aCL) antibody of IgG 
and/or IgM isotype in serum or plasma, 
present in medium or high titer (i.e.,  > 40 
GPL or MPL, or greater than the 99th 
percentile), on two or more occasions, at 
least 12 weeks apart, measured by a 
standardized ELISA, (3) anti-β2 glyco-
protein-I antibody of IgG and/or IgM 
isotype in serum or plasma (in titer greater 
than the 99th percentile), present on two or 
more occasions, at least 12 weeks apart, 
measured by a standardized ELISA, 
according to recommended procedures. 
 
Conclusion 
Anti-phospholipid antibody syndrome is 
a pro-thrombotic condition but with varied 
clinical presentation.19 Therefore, treatment 
needs to be individualized depending on the 
clinical presentation. Education regarding 
medication administration is essential. More 
research is required to understand the patho-
physiology of this syndrome, to validate the 
criteria, and to identify optimal 
treatment.20,21 
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Appendix
Revised Classification Criteria for the 
Antiphospholipid Antibody Syndrome22 
 
Clinical criteria (one or more) 
1. Vascular thrombosis: One or more 
objectively confirmed episodes of 
arterial, venous or small vessel 
thrombosis occurring in any tissue or 
organ. 
2. Pregnancy morbidity: a) one or more 
unexplained deaths of a morphologically 
normal fetus at or beyond the 10th week 
of gestation; or b) one or more 
premature births of a morphologically 
normal neonate before the 34th week of 
gestation because of eclampsia, pre-
eclampsia or placental insufficiency; or 
c) Three or more unexplained 
consecutive spontaneous abortions 
before the 10th week of gestation. 
 
Laboratory criteria: (one or more, 
present on 2 or more occasions at least 12 
weeks apart using recommended 
procedures) 
1. Lupus anticoagulant, detected according 
to the guidelines of the International 
Society on Thrombosis and 
Haemostasis. 
2. Anticardiolipin antibody of IgG and/or 
IgM isotype, present in medium or high 
titer (greater than 40 GPL or MPL, or 
greater than the 99th percentile), 
measured by a standardized ELISA 
3. Anti-β2-glycoprotein-1 antibody of IgG 
and/or IgM isotype, present in titer 
greater than the 99th percentile, 
measured by an ELISA. 
 
 
 
 
Current evidence-based guidelines for 
treatment18, 22 
1. Venous Thrombosis 
Distal leg DVT: 
a)  Severe symptoms: Treat with 
anticoagulants for three months 
b)  No/mild/moderate symptoms: No 
anticoagulation needed 
Proximal leg DVT 
a) 3 months, unless idiopathic (long 
term) 
Cancer associated DVT or PE 
a) Treat for at least 3 months and 
preferably long-term, unless bleeding 
risk very high 
Arterial Thrombosis 
a)  Aspirin or low/ moderate intensity 
anticoagulation (INR 1.5-2.5) 
b)  In patients with atrial fibrillation;  
warfarin or aspirin + clopidogrel 
 
It is recommended in the guidelines that 
patients who have had a first unprovoked 
(idiopathic/genetic) proximal DVT or 
pulmonary embolism be considered for 
long-term anticoagulation, independent of 
considerations such as the presence or 
absence of an identifiable genetic or 
acquired thrombophilia.22 If the patient 
develops another event while being on 
warfarin or aspirin, there is evidence that 
they should be put on warfarin with higher 
INR or warfarin with aspirin.18, 22 
 
